BRIEF⁠—Genmab to appeal Janssen award

Danish biotech Genmab this morning revealed that it has decided to file a request for review of the award dismissing its claims in the second arbitration arising under the license agreement with Johnson & Johnson subsidiary Janssen Biotech

The review of the award will be conducted by a single appeal arbitrator under the rules of the CPR Institute for Dispute Resolution for Non-Administered Arbitration.

The arbitration remains confidential, subject to the parties’ disclosure obligations under applicable law.

Other than pursuant to these obligations, Genmab does not intend to comment further or to provide additional information regarding the arbitration.